Cargando…

Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis

INTRODUCTION: The biologics abatacept and adalimumab have different mechanisms of action (MoAs). We analyzed data from patients with rheumatoid arthritis treated in AMPLE (NCT00929864) to explore the pharmacodynamic effects of abatacept or adalimumab on anti-citrullinated protein antibodies (ACPAs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jabado, Omar, Maldonado, Michael A., Schiff, Michael, Weinblatt, Michael E., Fleischmann, Roy, Robinson, William H., He, Aiqing, Patel, Vishal, Greenfield, Alex, Saini, Jasmine, Galbraith, David, Connolly, Sean E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964842/ https://www.ncbi.nlm.nih.gov/pubmed/34878629 http://dx.doi.org/10.1007/s40744-021-00404-x

Ejemplares similares

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
por: Degboé, Yannick, et al.
Publicado: (2020)

Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
por: Fleischmann, Roy, et al.
Publicado: (2016)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
por: Weinblatt, Michael E, et al.
Publicado: (2013)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
por: Fleischmann, Roy, et al.
Publicado: (2019)

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
por: Sokolove, Jeremy, et al.
Publicado: (2016)

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
por: Weijers, Laure, et al.
Publicado: (2017)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation
por: Verstappen, Marloes, et al.
Publicado: (2022)

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
por: Wells, Alvin F, et al.
Publicado: (2014)

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
por: Takahashi, Nobunori, et al.
Publicado: (2013)

Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis
por: Schiff, Michael, et al.
Publicado: (2016)

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
por: Park, Sang Hee, et al.
Publicado: (2020)

The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA
por: Suwannalai, Parawee, et al.
Publicado: (2011)

The Infectious Basis of ACPA-Positive Rheumatoid Arthritis
por: Sakkas, Lazaros I., et al.
Publicado: (2017)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical
por: Boeters, Debbie M., et al.
Publicado: (2017)

CCR6(+) Th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis
por: Paulissen, Sandra M. J., et al.
Publicado: (2015)

Tocilizumab Attenuates Anti-neutrophil Cytoplasmic Antibody-associated Nephritis Occurring during Abatacept and Adalimumab Therapy for Rheumatoid Arthritis
por: Yoshimura, Yusuke, et al.
Publicado: (2022)

Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial
por: Bandyopadhyay, Somnath, et al.
Publicado: (2017)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity
por: Cunningham, Kevin Y., et al.
Publicado: (2023)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis
por: Joshua, Vijay, et al.
Publicado: (2020)

A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis
por: Padyukov, Leonid, et al.
Publicado: (2010)

ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression
por: van Beers, Joyce JBC, et al.
Publicado: (2013)

The P. gingivalis Autocitrullinome Is Not a Target for ACPA in Early Rheumatoid Arthritis
por: Muñoz-Atienza, E., et al.
Publicado: (2020)

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept
por: Dervieux, Thierry, et al.
Publicado: (2019)

ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial
por: Seegobin, Seth D, et al.
Publicado: (2014)

High-specificity bioinformatics framework for epigenomic profiling of discordant twins reveals specific and shared markers for ACPA and ACPA-positive rheumatoid arthritis
por: Gomez-Cabrero, David, et al.
Publicado: (2016)

Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
por: Schiff, Michael, et al.
Publicado: (2016)

The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis
por: Kurowska, Weronika, et al.
Publicado: (2017)

ACPA Status Correlates with Differential Immune Profile in Patients with Rheumatoid Arthritis
por: Floudas, Achilleas, et al.
Publicado: (2021)

ACPA-negative rheumatoid arthritis: From immune mechanisms to clinical translation
por: Li, Ketian, et al.
Publicado: (2022)

The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis
por: Shafrin, Jason, et al.
Publicado: (2018)

An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting
por: van Heemst, Jurgen, et al.
Publicado: (2015)

Abatacept as a Therapeutic Option for Rheumatoid Vasculitis
por: Al Attar, Layth, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ciksa9402g7l0l35beb3odd37c